Expert Interview
Discussing the recent approval of Zynyz (Retifanlimab) from Incyte in merkel cell carcinoma (MCC).
Ticker(s): MRK, INCYInstitution: Lahey Clinic Hospital based in Boston, MA
- Medical Director of the Cancer Center.
- Special interests in gastrointestinal cancers, head and neck cancers, breast cancers, lung cancers, Genitourinary cancers, Melanoma, aerodigestivetract disease and lymphomas.
- Trained at Michigan State University in Lansing, MI. Completed Residency at Caritas Carney Hospital (Internal Medicine), Boston, MA, 2003-2006, and Fellowship at Michigan StateUniversity, Breslin Cancer Center (Oncology and Hematology), Lansing, 2006-2009.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
